QEEG Correlates of Auditory-Visual Entrainment Treatment Efficacy of Refractory Depression
Abstract
Introduction. It is well established that the number of people diagnosed and suffering from depression is on the increase. Many of these patients are not responsive to firstline pharmacological intervention or simply cannot use medications for other reasons. As such, there has been a growing need for nonmedication approaches to treatment. The purpose of this study was to examine the use of auditory-visual EEG entrainment (AVE) at a 14 Hz (beta) frequency to decrease symptoms of depression with corresponding changes in neurophysiology. Method. Sixteen participants ranged in age from 20 to 67 years and were screened utilizing the Beck Depression Inventory–II (BDI–II) and broken into two groups of 8 (simulated, AVE treatment groups), with a cross-over design. Both groups were given the BDI–II and QEEG testing at baseline, 4 weeks following either AVE or simulated treatment, and then again after an additional 4 weeks and a switch in treatment in the cross-over design. Results. Results revealed significant reduction of depression only after the 4 weeks on AVE therapy of the BDI–II scores (p>.01). QEEG scores adjusted for normal age deviations demonstrate significant EEG change scores over time in cortical regions associated with mood regulation. Conclusion. The findings indicate that AVE therapy may be a viable nonmedication therapeutic intervention.
Published
2016-09-02
Issue
Section
SCIENTIFIC FEATURES
© International Society for Neurofeedback and Research (ISNR), all rights reserved. This article (the “Article”) may be accessed online from ISNR at no charge. The Article may be viewed online, stored in electronic or physical form, or archived for research, teaching, and private study purposes. The Article may be archived in public libraries or university libraries at the direction of said public library or university library. Any other reproduction of the Article for redistribution, sale, resale, loan, sublicensing, systematic supply, or other distribution, including both physical and electronic reproduction for such purposes, is expressly forbidden. Preparing or reproducing derivative works of this article is expressly forbidden. ISNR makes no representation or warranty as to the accuracy or completeness of any content in the Article. From 1995 to 2013 the Journal of Neurotherapy was the official publication of ISNR (www. Isnr.org); on April 27, 2016 ISNR acquired the journal from Taylor & Francis Group, LLC. In 2014, ISNR established its official open-access journal NeuroRegulation (ISSN: 2373-0587; www.neuroregulation.org).